News

VIDEO: Exploring SYMPLICITY’s failure, Part 2


 

AT ACC 14

WASHINGTON – Far from being doomed after the failure SYMPLICITY HTN-3, renal denervation for refractory hypertension will continue to be explored. But it can’t go very far without finding a way to measure its effectiveness.

In Part 2 of our interview, Dr. Prakash Deedwania and Dr. George Bakris explore the options, and don’t miss the chance to talk about the controversial new hypertension guidelines.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

mzoler@frontlinemedcom.com

On Twitter @mitchelzoler

Recommended Reading

New stroke guidelines focus on women’s risks
MDedge Cardiology
Beta-blockers lose luster for hypertension therapy
MDedge Cardiology
The demise of renal artery stenting
MDedge Cardiology
First guidelines on pulmonary hypertension in sickle cell disease released
MDedge Cardiology
Childhood glomerular disease associated with adult hypertension
MDedge Cardiology
Systolic variability after intracerebral hemorrhage raises odds of death, disability
MDedge Cardiology
VIDEO: What explains SYMPLICITY HTN-3’s failure?
MDedge Cardiology
Ineffective renal denervation blamed for trial’s failure
MDedge Cardiology
Too much or too little sodium may boost cardiovascular risk
MDedge Cardiology
One in four patients with hypertension nonadherent to therapy
MDedge Cardiology

Related Articles